MA-ABIOMED
20.9.2022 02:25:27 CEST | Business Wire | Press release
Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place in Boston.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005279/en/
Caption: The investigator-led Inova, NCSI and J-PVAD studies all demonstrate an improvement from the historical AMI cardiogenic shock survival rate of approximately 50% when patients are treated with best practices including Impella. (Graphic: Business Wire)
The analysis examined 293 consecutive Impella-supported AMICS patients in the J-PVAD Registry, a registry conducted by 10 Japanese professional societies, including the Japanese Circulation Society (JCS). Results demonstrated 81% survival at 30 days. Historical cardiogenic shock survival rates without Impella are approximately 50%.
“The results of this study demonstrate that when Impella is used and best practices are followed, it is possible to achieve heart recovery and greater than 80% survival rates for patients with AMI cardiogenic shock,” said lead investigator Junya Ako, MD, an interventional cardiologist and chair of the department of cardiovascular medicine at Kitasato University Hospital in Kanagawa.
These results are consistent with other published investigator-led studies, such as the National Cardiogenic Shock Initiative Study (NCSI) and the Inova study by Tehrani et al., that have demonstrated significant increases in survival with the use of Impella and best practices such as placing Impella prior to percutaneous coronary intervention (PCI) (see figure 1).
J-PVAD data is independently monitored and shared with the Japan Pharmaceuticals and Medical Devices Agency (PMDA).
ABOUT IMPELLA HEART PUMPS
Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed (ABMD), is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: http://www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005279/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Allianz Achieves Record Operating Profit of 17.4 Billion Euros – Excellent Start to New Strategic Cycle26.2.2026 07:16:00 CET | Press release
12M 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225107874/en/ Oliver Bäte, Chief Executive Officer of Allianz SEExcellent momentum and record operating profitTotal business volume rises 8.11 percent and reaches 186.9 billion euros with contributions from all segments Operating profit increases 8.4 percent to 17.4 billion euros, our highest operating profit ever Shareholders’ core net income advances 10.9 percent to 11.1 billion euros Core earnings per share (EPS) grow 12.5 percent and reach 28.61 euros Core return on equity (RoE) reaches an excellent level of 18.1 percent Solvency IIratio2 increases 10 percentage points to 218 percent supported by excellent capital generation 4Q 2025 Diversified growth and double-digit increase in shareholders’ core net incomeTotal business volume rises 6.5 1 percent with contributions from all segments Operating profit increases 3.0 percent to 4.3 billion euros, driven by excelle
Tigo Energy Showcases Real-time Active Commissioning Software at KEY 2026 Expo26.2.2026 06:00:00 CET | Press release
Next-generation commissioning system designed to help streamline solar installations delivers another Total Quality Solar innovation as Tigo expands installer loyalty program Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo,” “Company”), a leading provider of intelligent solar and energy software solutions, today announced the Company’s presence as an exhibitor at the 2026 KEY – The Energy Transition Expo in Rimini, Italy, where Tigo will preview the new active commissioning software. From basic solar-only installations to advanced solar-plus-storage configurations, the system supports installers throughout the entire jobsite workflow via the Tigo EI App, delivering on-site guidance, real-time progress visibility, and clear verification of every required step to help reduce delays, truck rolls, and commissioning uncertainty. At KEY 2026, Tigo will also showcase the latest expansions to the Installer Loyalty Program, including new eligibility tiers and segments, enhanced data support for install
Indra Group Exceeds All Its Guidances in 2025 and Sets Even More Ambitious Guidances for 2026 Than Those Set Out in Its 'Leading the Future' Strategic Plan25.2.2026 23:08:00 CET | Press release
Results in fiscal year 2025Revenues increased by 13%, totaling €5.457 billion in 2025Indra Group sets financial guidances at least 17% higher than those foreseen in its Strategic Plan for 2026Indra Group announces thepayment of a €0.30 dividend per share (more than 20% above the dividend in 2024) charged to the earnings posted in 2025The results and the increase in the order intake confirm Indra Group’s industrial strength and its capacity to tackle and execute the major defence modernization programs Indra Group (MAD:IDR): • The fourth-quarter order intake in 2025 totaled €8.329 billion, raising thefull-year backlog to €16.083 billion (122% more than in 2024). The Defence backlog stood at €11.336 billion, far exceeding the target of more than €10 billion set for 2026. • Revenues increased by 13% in 2025 with respect to 2024, with double-digit year-on-year rises in Defence, ATM and Mobility Revenues recorded a 28% year-on-year rise in the final quarter of the year • EBITDA and EBIT rec
Belkin Introduces a New Accessory Collection for Samsung Galaxy S26 Series25.2.2026 19:00:00 CET | Press release
Including five ‘Designed for Samsung’ accessories plus more, the collection is engineered and optimized specifically for the Samsung Galaxy S26 seriesFrom fast Qi2 25W charging to Nano-Titan–enhanced screen protection, each product is engineered for everyday performance and durabilityThe lineup reinforces Belkin’s role as a trusted partner for next-generation Galaxy devices Belkin, a leading consumer electronics brand for over 40 years, today announced a new collection of accessories designed and optimized specifically for the Samsung Galaxy S26 series. From fast, reliable Qi2 25W charging to advanced screen protection engineered for ultrasonic fingerprint sensors and next-generation displays, every product in the collection is designed to meet the demands of Galaxy S26 users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225459906/en/ Belkin Introduces a New Accessory Collection for Samsung Galaxy S26 Series ‘Designed f
Andersen Consulting udvider sine kompetencer med Assure Consulting25.2.2026 18:58:00 CET | Pressemeddelelse
Andersen Consulting styrker sin platform med tilføjelsen af samarbejdspartneren Assure Consulting, et tysk managementkonsulentfirma med speciale i projektledelse og projektporteføljestyring. Assure Consulting blev grundlagt i 2003 og hjælper organisationer med at gennemføre komplekse projekter og transformationer. Firmaet hjælper kunder med at etablere og drive projektkontorer (PMO'er), styrke governance og porteføljestyring samt anvende klassiske, agile eller hybride projektledelsesmetoder, der er skræddersyet til deres behov. Assure Consulting yder også praktisk støtte til udrulning af store systemer og processer, integreret forandringsledelse i forbindelse med organisatoriske og kulturelle transformationer samt coaching- og træningsprogrammer, der er i overensstemmelse med internationalt anerkendte standarder for projektledelse, med henblik på at opbygge bæredygtige kompetencer i kundernes organisationer. "Dette samarbejde giver os mulighed for at skalere vores ekspertise inden for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom